MCM
IMVT icon

MAI Capital Management’s Immunovant IMVT Stock Holding History

MAI Capital Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$497 Buy
+20
New +$518 ﹤0.01% 4421

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

MAI Capital Management's IMVT Position: Q1 2026 in Review

MAI Capital Management opened a new position in Immunovant (IMVT) in Q1 2026: 20 shares worth $497. The stake represents ﹤0.01% of the portfolio and ranks #4421 among its holdings.

215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

  • MAI Capital Management held 20 shares of Immunovant worth $497 as of Q1 2026.
  • Immunovant was a new MAI Capital Management position in Q1 2026.
  • Immunovant made up ﹤0.01% of MAI Capital Management's portfolio in Q1 2026, its #4421 holding.
  • 215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on MAI Capital Management's 13F filing for Q1 2026, filed 15 May 2026.